Published on 19/09/2019 11:45:47 AM | Source: Reliance Securities Ltd

Buy Aurobindo Pharma Ltd For Target Rs.860 - Reliance Securities

Posted in Broking Firm Views - Short Term Report| #Pharma Sector #Aurobindo Pharma Ltd #Trading Report #Reliance Securities Ltd

Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel 

Download Telegram App before Joining the Channel


* Aurobindo Pharma (ARBP) is a mid-sized Indian pharma company with one of the largest product portfolios in the US market. Formulation business contributes ~87% to its total sales, while the contribution of API business stands at ~13%.

* With seven marketed oncology injectable products addition and recent Sandoz’s derma and oral solid business acquisition (deal to close by 2HFY20E), we see significant scale in the US operation. Overall business-mix changed towards high-growth and high-margin complex generic segment and we expect this mix to continue in the near future. 40 new products expected to be launched in FY20 in the US.

* Despite challenging environment in the US, we expect ARBP’s US revenue to clock 37% CAGR over FY19-21E led by new launches (139 pending for approval), ramp-up in injectable and contribution from Sandoz and Spectrum acquisition.

* With double-digit margin in European business, we expect further improvement in margin led by cost savings following transfer of products from Europe to Indian manufacturing units.

* At CMP, the stock trades at a discount to its peers owing to higher leverage and pending USFDA issues. We maintain our BUY recommendation on the stock with a Target Price of Rs860.


To Read Complete Report & Disclaimer Click Here


For More Reliance Securities Ltd disclaimer at SEBI registration No. INH000002384


Above views are of the author and not of the website kindly read disclaimer